Page 2,357«..1020..2,3562,3572,3582,359..2,3702,380..»

Missoula Youth Symphony's Concert in the Dark to shine light on eye disease

Posted: Published on March 20th, 2015

Darkness has been a theme in the life of Emily Graham, who is organizing the Concert in the Dark to promote awareness about retinitis pigmentosa. Graham, a Hellgate High School senior, was diagnosed with the genetic disease when she was 2 years old. During Saturday's performance, the Innocent Bystanders Brass Band and David Harmsworth will perform entirely in the dark to give that sense of having to rely on your other senses, Graham said. The Missoula Youth Symphony, in which Graham plays the viola, also will perform and blindfolds will be available for people who want to continue listening in darkness. After the performances, an auction will take place during which participants will wear blindfolds and bid in the dark. The event is to help raise money for research and awareness about retinitis pigmentosa, which causes vision disintegration and leads to blindness. About 100,000 people have the disease that usually makes them legally blind by the age of 40, according to the Foundation Fighting Blindness. Im definitely on the better end of the spectrum, Graham said, adding that she has trouble adjusting to sudden changes in lighting and night blindness. Still, knowing that she likely will go blind has been … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Missoula Youth Symphony's Concert in the Dark to shine light on eye disease

Stem Cell Transplant for Autism – Video

Posted: Published on March 20th, 2015

Stem Cell Transplant for Autism 4 years old boy shows improvements after Stem Cell Transplant for Autism. Eye contact improved. Sitting tolerance improved. Observation skills have improved. Command following has improved.... By: Neurogen Brain and Spine Institute … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Stem Cell Transplant for Autism – Video

New Drug May Help Keep Hodgkin Lymphoma at Bay

Posted: Published on March 20th, 2015

WEDNESDAY, March 18, 2015 (HealthDay News) -- An FDA-approved drug doubled the amount of time that patients with Hodgkins lymphoma survived without any progression in their disease, a new study shows. All of the patients also received stem cell therapy along with the drug, called brentuximab vedotin. While the results are encouraging, doctors may never know if the drug is actually lengthening patients' lives, said Dr. Owen O'Connor, director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York City. That's because brentuximab is fast becoming standard care for all patients with Hodgkin lymphoma who've relapsed after stem cell transplant, he said. So, a trial comparing the survival of patients who got the drug against those who did not might never be feasible, due to ethical concerns. O'Connor was not involved in the trial, which was led by Dr. Craig Moskowitz, professor of medicine at Memorial Sloan Kettering Cancer Center in New York City. His team published the findings March 18 in The Lancet. The study was funded by Seattle Genetics Inc. and drug maker Takeda. According to the American Cancer Society, about 9,000 new cases of Hodgkin lymphoma are diagnosed each year, and more than … Continue reading →

Posted in Stem Cell Transplant | Comments Off on New Drug May Help Keep Hodgkin Lymphoma at Bay

The Lancet: Targeted drug doubles progression free survival in Hodgkin lymphoma

Posted: Published on March 20th, 2015

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months). The findings, published in The Lancet, are potentially practice changing for this young cancer population who have exhausted other treatment options and for whom prognosis is poor. "No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma"*, says lead author Craig Moskowitz, a Professor of Medicine at Memorial Sloan Kettering Cancer Center, New York, USA. Hodgkin lymphoma is the most common blood cancer in young adults aged between 15 and 35 years. Most patients are cured with chemotherapy or radiotherapy. However, for patients who relapse, or do not respond to initial therapy, the treatment of choice is usually a combination of high-dose chemotherapy and autologous stem cell transplant (ASCT)--a procedure that uses healthy stem cells from the patient to replace those lost to disease or chemotherapy. While about 50% of patients who undergo this procedure are cured, for the other half treatment is palliative. … Continue reading →

Posted in Stem Cell Transplant | Comments Off on The Lancet: Targeted drug doubles progression free survival in Hodgkin lymphoma

About my feeling on aesthetic medicine – Video

Posted: Published on March 20th, 2015

About my feeling on aesthetic medicine By: Yee Chong … Continue reading →

Posted in Aesthetic Medicine | Comments Off on About my feeling on aesthetic medicine – Video

Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM – Video

Posted: Published on March 20th, 2015

Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM http://r3stemcell.com/stem-cell-treatments/amniotic-derived-stem-cell-injections/ Amniotic derived stem cell therapy has become exceptionally popular due to the benefits that are being seen.... By: R3 Stem Cell … Continue reading →

Comments Off on Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM – Video

Stem cells show promise for reversing type 2 diabetes

Posted: Published on March 20th, 2015

IMAGE:This is an image of macro-encapsulated pancreatic endocrine cells derived from human embryonic stem cells. Devices were harvested at 29 weeks post-transplant and immunofluorescent staining was performed for insulin... view more Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs. Stem cells - generic cells that haven't yet taken on specialized form and function - have recently been used by scientists at UBC and elsewhere to reverse Type 1 diabetes in mice. In Type 1 diabetes, which usually begins in childhood, the pancreas produces little or no insulin, the hormone that enables cells to metabolize sugar. These new results, published today in Stem Cell Reports, hold much broader potential because Type 2 diabetes - which usually arises in adulthood, often stemming from poor diet, lack of exercise and obesity - accounts for more than 90 per cent of diabetes cases. Timothy Kieffer, a professor in the department of cellular and physiological sciences, and scientists from BetaLogics simulated Type 2 diabetes in mice by putting them on a high-fat, … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stem cells show promise for reversing type 2 diabetes

Stem cell "mini-lungs" created in Cambridge University lab

Posted: Published on March 20th, 2015

Comments(0) Cambridge stem cell scientists searching for new cystic fibrosis treatments have grown "mini-lungs" in a laboratory. The millimetre-wide cell clusters were created using stem cells derived from the skin of patients with the devastating lung disease. They are the latest in a line of 3D "organoids" produced to mimic the behaviour of specific body tissues, following "mini-brains" for studying Alzheimer's disease and "mini-livers" to model diseases of the liver. Dr Nick Hannan, led the team from Cambridge University. He said: "In a sense, what we've created are 'mini-lungs'. "While they only represent the distal (outer) part of lung tissue, they are grown from human cells and so can be more reliable than using traditional animal models, such as mice. "We can use them to learn more about key aspects of serious diseases - in our case, cystic fibrosis." Cystic fibrosis occurs when the movement of water to the inside of the lungs is reduced, causing a build up of thick mucus that leads to a high risk of infection. The scientists reprogrammed ordinary skin cells to create stem cells that could be transformed into lung tissue. More: Stem cell "mini-lungs" created in Cambridge University lab … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stem cell "mini-lungs" created in Cambridge University lab

First stem cell-based approach to treat type 2 diabetes effective in mice

Posted: Published on March 20th, 2015

IMAGE:This is an image of macro-encapsulated pancreatic endocrine cells derived from human embryonic stem cells. Devices were harvested at 29 weeks post-transplant and immunofluorescent staining was performed for insulin (red),... view more A combination of human stem cell transplantation and antidiabetic drugs proved to be highly effective at improving body weight and glucose metabolism in a mouse model of type 2 diabetes. The findings, published March 19th by Stem Cell Reports, could set the stage for clinical trials to test the first stem cell-based approach for insulin replacement in patients with type 2 diabetes. Type 2 diabetes, which accounts for 90%-95% of the now approaching 400 million cases of diabetes worldwide, is currently treated by oral medication, insulin injections, or both to control blood glucose levels. However, insulin delivery is imprecise, onerous, and often promotes weight gain, while drugs do not work in some patients and may cause gastrointestinal problems or low blood glucose levels, highlighting the strong need for better treatment options. To address this need, senior study author Timothy Kieffer of the University of British Columbia collaborated with BetaLogics, a division of Janssen Research & Development, LLC, and tested a promising stem cell transplantation approach. First, they fed … Continue reading →

Comments Off on First stem cell-based approach to treat type 2 diabetes effective in mice

Targeted drug doubles progression free survival in Hodgkin lymphoma

Posted: Published on March 20th, 2015

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months). The findings, published in The Lancet, are potentially practice changing for this young cancer population who have exhausted other treatment options and for whom prognosis is poor. "No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma", says lead author Craig Moskowitz, a Professor of Medicine at Memorial Sloan Kettering Cancer Center, New York, USA. Hodgkin lymphoma is the most common blood cancer in young adults aged between 15 and 35 years. Most patients are cured with chemotherapy or radiotherapy. However, for patients who relapse, or do not respond to initial therapy, the treatment of choice is usually a combination of high-dose chemotherapy and autologous stem cell transplant (ASCT)--a procedure that uses healthy stem cells from the patient to replace those lost to disease or chemotherapy. While about 50% of patients who undergo this procedure are cured, for the other half treatment is palliative. … Continue reading →

Comments Off on Targeted drug doubles progression free survival in Hodgkin lymphoma

Page 2,357«..1020..2,3562,3572,3582,359..2,3702,380..»